Tearsheet

vTv Therapeutics (VTVT)

Market Price (11/15/2025): $30.39 | Market Cap: $200.2 Mil
Sector: Health Care | Industry: Biotechnology

vTv Therapeutics (VTVT)

Market Price (11/15/2025): $30.39
Market Cap: $200.2 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13%	Trading close to highs Dist 52W High is -1.5%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -26 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -150718%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.	Weak multi-year price returns 3Y Excs Rtn is -96%	Expensive valuation multiples P/SPrice/Sales ratio is 11934x
2			Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -98%
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -129559%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -129559%
4			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 6397%
5			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
2	Trading close to highs Dist 52W High is -1.5%
3	Weak multi-year price returns 3Y Excs Rtn is -96%
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -26 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -150718%
5	Expensive valuation multiples P/SPrice/Sales ratio is 11934x
6	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -98%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -129559%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -129559%
8	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 6397%
9	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14%

Market Valuation & Key Metrics

	11/15/25	2024	2023	2022	2021
Share Price CYE	$30.39	$13.81	$11.50	$26.51	$39.80
Market Cap CYE ($ Mil)	200.2	91.0	24.0	59.1	74.0
Total Debt ($ Mil)	0.1	0.2	0.5	0.7	0.9
Total Cash ($ Mil)	25.9	36.7	9.4	12.1	13.4
Enterprise Value ($ Mil)	174.3	91.2	24.5	59.8	74.9
Valuation Ratios
P/S TTM	11775.4	78.4	0.0	25.2	15.6
P/EBIT TTM	-8.2	-3.5	-0.9	-2.0	-3.5
P/E TTM	-10.2	-4.3	-1.2	-2.7	-4.8
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0	4.6	7.3
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3	-1.3	-2.7
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8

	11/15/25	2024	2023
Share Price CYE	$30.39	$13.81	$11.50
Market Cap CYE ($ Mil)	200.2	91.0	24.0
Total Debt ($ Mil)	0.1	0.2	0.5
Total Cash ($ Mil)	25.9	36.7	9.4
Enterprise Value ($ Mil)	174.3	91.2	24.5
Valuation Ratios
P/S TTM	11775.4	78.4	0.0
P/EBIT TTM	-8.2	-3.5	-0.9
P/E TTM	-10.2	-4.3	-1.2
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3
P/E TTM (Sector)	-1.7	-1.5	-1.5

	VTVT	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	0.0
Rev Chg Q	�	7.1%
Rev Chg LTM	-98.3%	6.1%
Rev Chg 3Y Avg	3,604.3%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-150,717.6%	18.8%
CFO/Rev LTM	-129,558.8%	20.5%
Net Inc Mgn	-115,029.4%	13.1%
VALUATION	VERY HIGH
P/S	11,775.4	3.2
P/CFO	-9.1	15.0
P/FCF	-9.1	20.0
P/E	-10.2	23.4
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.98	0.07

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Number of Drugs in Pipeline	7	11062025	Link
Number of Clinical Trials	1	8072025	Link
Number of Employees	23	12312023	Link
Number of Patents	39	9282021	Link

VTVT Stock

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

During the approximate time period from July 31, 2025, to November 15, 2025, vTv Therapeutics (VTVT) experienced a 106% stock increase due to several key developments related to its lead drug candidate, cadisegliatin, and a significant financial infusion.

1. Successful $80 Million Private Placement. In September 2025, vTv Therapeutics announced the successful closing of an $80 million private placement. This substantial capital infusion significantly strengthened the company's balance sheet, providing critical funding for the ongoing Phase 3 CATT1 trial and continued development of the cadisegliatin program.

2. First Patient Randomized in Phase 3 CATT1 Trial. In August 2025, vTv Therapeutics announced the randomization of the first study participant in its CATT1 Phase 3 trial. This milestone represents a crucial advancement in the clinical development of cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, moving the drug closer to potential market approval.

Stock Movement Drivers

Fundamental Drivers

The 99.5% change in VTVT stock from 8/15/2025 to 11/14/2025 was primarily driven by a 99.5% change in the company's P/S Multiple.

	8152025	11142025	Change
Stock Price ($)	15.44	30.80	99.48%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.02	0.02	0.00%
P/S Multiple	5982.61	11934.22	99.48%
Shares Outstanding (Mil)	6.59	6.59	0.00%
Cumulative Contribution			99.48%

LTM = Last Twelve Months as of date shown

Market Drivers

8/15/2025 to 11/14/2025

	Return	Correlation
VTVT	99.5%
Market (SPY)	4.4%	11.9%
Sector (XLV)	11.5%	26.3%

Fundamental Drivers

The 46.5% change in VTVT stock from 5/16/2025 to 11/14/2025 was primarily driven by a 46.6% change in the company's P/S Multiple.

	5162025	11142025	Change
Stock Price ($)	21.03	30.80	46.46%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.02	0.02	0.00%
P/S Multiple	8143.37	11934.22	46.55%
Shares Outstanding (Mil)	6.58	6.59	-0.06%
Cumulative Contribution			46.46%

LTM = Last Twelve Months as of date shown

Market Drivers

5/16/2025 to 11/14/2025

	Return	Correlation
VTVT	46.5%
Market (SPY)	13.4%	1.6%
Sector (XLV)	14.6%	15.2%

Fundamental Drivers

The 96.9% change in VTVT stock from 11/14/2024 to 11/14/2025 was primarily driven by a 13883.1% change in the company's P/S Multiple.

	11142024	11142025	Change
Stock Price ($)	15.64	30.80	96.91%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	1.00	0.02	-98.30%
P/S Multiple	85.35	11934.22	13883.08%
Shares Outstanding (Mil)	5.46	6.59	-20.72%
Cumulative Contribution			88.45%

LTM = Last Twelve Months as of date shown

Market Drivers

11/14/2024 to 11/14/2025

	Return	Correlation
VTVT	96.9%
Market (SPY)	14.3%	25.9%
Sector (XLV)	6.4%	21.3%

Fundamental Drivers

The -12.5% change in VTVT stock from 11/15/2022 to 11/14/2025 was primarily driven by a -227.3% change in the company's Shares Outstanding (Mil).

	11152022	11142025	Change
Stock Price ($)	35.20	30.80	-12.51%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	2.02	0.02	-99.16%
P/S Multiple	35.10	11934.22	33897.00%
Shares Outstanding (Mil)	2.01	6.59	-227.35%
Cumulative Contribution			-464.72%

LTM = Last Twelve Months as of date shown

Market Drivers

11/15/2023 to 11/14/2025

	Return	Correlation
VTVT	119.4%
Market (SPY)	52.9%	12.8%
Sector (XLV)	22.1%	8.4%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
VTVT Return	9%	-47%	-33%	-57%	20%	126%	-54%
Peers Return	-15%	-9%	-6%	-3%	-3%	-17%	-44%
S&P 500 Return	16%	27%	-19%	24%	23%	15%	109%
Monthly Win Rates [3]
VTVT Win Rate	50%	25%	33%	17%	50%	50%
Peers Win Rate	18%	15%	23%	31%	22%	62%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
VTVT Max Drawdown	-12%	-49%	-60%	-68%	-31%	-3%
Peers Max Drawdown	-20%	-13%	-14%	-15%	-30%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 11/14/2025 (YTD)

How Low Can It Go

Unique Key	Event	VTVT	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-93.8%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1518.8%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-60.3%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	151.7%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	Not Fully Recovered days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-91.1%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	1018.1%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days

Compare to VRTX, APM, BBOT, GDTC, HIND

In The Past

vTv Therapeutics's stock fell -93.8% during the 2022 Inflation Shock from a high on 4/13/2021. A -93.8% loss requires a 1518.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About vTv Therapeutics (VTVT)

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

AI Generated Analysis | Feedback

Here are 1-3 brief analogies to describe vTv Therapeutics (VTVT):

Like a pre-breakthrough Moderna, but developing treatments for diabetes and neurological diseases instead of vaccines.
An early-stage Eli Lilly, focused solely on developing a few key oral drugs for diabetes.

AI Generated Analysis | Feedback

TTP399: An oral glucokinase activator undergoing development as an adjunctive treatment for Type 1 Diabetes.
HPP737: An oral phosphodiesterase 4 (PDE4) inhibitor being developed for the treatment of inflammatory diseases like psoriasis and atopic dermatitis.

AI Generated Analysis | Feedback

vTv Therapeutics (VTVT) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule drug candidates. As such, it does not sell approved pharmaceutical products directly to individuals or through traditional commercial channels to distributors or pharmacies.

Instead, vTv Therapeutics generates revenue primarily through collaboration and licensing agreements with other pharmaceutical and biotechnology companies that are interested in further developing and commercializing its drug candidates.

Based on its recent SEC filings and business activities, its major customer and partner for licensing its drug programs is:

CinRx Pharma, LLC (private company, no public symbol)

AI Generated Analysis | Feedback

IQVIA Holdings Inc. (IQV)
Parexel International

AI Generated Analysis | Feedback

Paul Sekhri Chairman, President and Chief Executive Officer

Mr. Sekhri has over 35 years of experience in the Life Science Industry, with senior management roles in large corporate pharmaceutical and biotechnology companies, as well as private equity and venture capital. He is currently Chairman, President, and Chief Executive Officer of vTv Therapeutics, Inc. Mr. Sekhri previously served as President and CEO of eGenesis, Inc. from 2019 to 2022 and Lycera Corp. from 2015 to 2018. His past experience includes Senior Vice President, Integrated Care for Sanofi, Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd., and five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, a life sciences venture capital arm of TPG Capital. Mr. Sekhri founded Cerimon Pharmaceuticals, Inc., serving as its President and Chief Executive Officer from 2004 to 2009. He also held positions as President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. and Senior Vice President, Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG.

Dr. Michael Tung Chief Financial Officer

Dr. Tung earned B.A. and B.S. degrees in economics and biology from The George Washington University, and a combined M.D./MBA from Tufts University School of Medicine. He is a licensed physician in the states of Massachusetts and New York. He was appointed Executive Vice President, effective May 19, 2025, and is listed as the Chief Financial Officer.

Carmen Valcarce, Ph.D. Executive Vice President, Chief Scientific Officer

Dr. Valcarce possesses over 30 years of pharmaceutical research and development experience, primarily focused on the metabolic space. She was instrumental in the clinical development of TTP399, vTv's Glucokinase Activator program, and was a member of the vTv IPO team, joining the company through its partnership with Novo Nordisk. Throughout her career, she has managed more than 12 Investigational New Drug (IND) applications and successfully conducted numerous clinical studies in the field of diabetes.

Rich Nelson Executive Vice President, Corporate Development

Mr. Nelson brings more than 25 years of experience in mergers, acquisitions, and capital raising. He also serves as Executive Vice President Corporate Development for Vericast, where he is responsible for identifying and executing global merger and acquisition opportunities. His previous roles include Senior Vice President of Global Corporate Development at The Nielsen Company, Managing Director, Mergers and Acquisitions at IAC/InterActive Corp., and President and Co-Founder of Trendum (now Nielsen BuzzMetrics). He was also SVP/General Counsel of RSL Communications and started his career as a mergers and acquisition attorney at Skadden Arps. Mr. Nelson served as Acting Chief Executive Officer of vTv Therapeutics in March 2022. He is an active venture investor and advisor to various stage private companies.

Barry Brown Chief Accounting Officer

Mr. Brown serves as the Chief Accounting Officer for vTv Therapeutics.

AI Generated Analysis | Feedback

The advancement of cell therapies, particularly stem cell-derived islet cell transplantation therapies such as Vertex Pharmaceuticals' VX-880 for Type 1 Diabetes (T1D), represents a clear emerging threat. While vTv Therapeutics' TTP399 aims to improve glycemic control and reduce insulin requirements in T1D patients through a daily oral medication, cell therapies like VX-880 are demonstrating the potential for a functional cure and insulin independence. If these curative therapies prove successful, scalable, and widely adopted, they could significantly diminish the market potential and need for long-term T1D management drugs like TTP399.

AI Generated Analysis | Feedback

vTv Therapeutics (VTVT) is a clinical-stage biopharmaceutical company primarily focused on developing treatments for type 1 diabetes and psoriasis. The addressable markets for its main product candidates are as follows:

Cadisegliatin (TTP399) for Type 1 Diabetes

vTv Therapeutics' lead product candidate, cadisegliatin (TTP399), is an oral, liver-selective glucokinase activator being developed as an adjunctive therapy to insulin for type 1 diabetes (T1D). The addressable market for Type 1 Diabetes treatments is substantial:

Globally, the Type 1 Diabetes market was estimated at approximately USD 15.5 billion in 2024 and is projected to reach USD 21.2 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 5.4% from 2024 to 2030. Other estimates place the global market at USD 16.97 billion in 2025, expanding to USD 26.22 billion by 2032 with a CAGR of 6.4%. Another report estimates the global market at USD 34.87 billion in 2024, potentially reaching around USD 74.03 billion by 2034 with a CAGR of 7.82%.
In the U.S. alone, the Type 1 Diabetes market was valued at USD 4.2 billion in 2024. The U.S. market size for type 1 diabetes treatment was USD 2573.47 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Another source projects the U.S. market at USD 11.23 billion in 2024, anticipated to reach around USD 24.27 billion by 2034, growing at a CAGR of 8% between 2024 and 2034.
Across the top seven major markets (U.S., EU4, U.K., and Japan), the Type 1 Diabetes market reached a value of USD 5.9 billion in 2024, with a projected growth to USD 9.6 billion by 2035 at a CAGR of 4.65%.

HPP737 for Psoriasis

HPP737 is an orally administered phosphodiesterase type 4 (PDE4) inhibitor under development for the treatment of psoriasis. The addressable market for psoriasis therapeutics is significant:

The global psoriasis therapeutics market was valued at USD 22.9 billion in 2021 and is projected to reach USD 55.8 billion by 2031, demonstrating a CAGR of 9.3% from 2022 to 2031.
Another estimate indicates the global psoriasis drugs market was approximately USD 35 billion in 2025, with a projected CAGR of around 12% through 2033.
The global psoriasis treatment market size was valued at USD 27.20 billion in 2024 and is projected to grow from USD 29.15 billion in 2025 to USD 57.68 billion by 2032, exhibiting a CAGR of 10.2%.
North America is a dominant region in the psoriasis treatment market, holding a 74.71% market share in 2024.

AI Generated Analysis | Feedback

The expected drivers of future revenue growth for vTv Therapeutics (VTVT) over the next 2-3 years are primarily linked to the advancement and potential commercialization of its lead drug candidate, cadisegliatin.

Successful Completion and Positive Results from the Phase 3 CATT1 Trial for Cadisegliatin in Type 1 Diabetes (T1D): vTv Therapeutics is currently conducting the Phase 3 CATT1 trial for cadisegliatin as an adjunctive therapy to insulin for treating type 1 diabetes. The company randomized its first patient in August 2025 and anticipates disclosing topline data from this study in the second half of 2026. Positive results from this pivotal trial are crucial for regulatory submissions and eventual market approval, which would be the primary driver of future revenue.
Initiation and Progress of International Registrational Trials for Cadisegliatin in T1D: In parallel with the U.S. Phase 3 study, vTv Therapeutics is planning to initiate two international registrational trials for cadisegliatin in type 1 diabetes, with commencement expected in 2026. These trials will be key to expanding the potential market for cadisegliatin beyond the United States, driving international revenue growth in the future.
Successful Completion and Positive Results from the Phase 2 Trial of Cadisegliatin in Type 2 Diabetes (T2D): The company is collaborating with G42 Investments to launch a Phase 2 trial in the Middle East, evaluating cadisegliatin in 450 type 2 diabetes patients currently on insulin therapy. This trial is on track to begin in the second half of 2024. Positive outcomes from this Phase 2 study could pave the way for further development in the larger Type 2 diabetes market, representing a significant long-term revenue opportunity.
Leveraging an Expanded U.S. Patent Portfolio for Cadisegliatin: vTv Therapeutics has been expanding its U.S. patent portfolio for cadisegliatin. A U.S. patent covering crystalline salts and co-crystals of cadisegliatin was allowed, with exclusivity expected through 2041. This intellectual property protection provides a prolonged period of market exclusivity, safeguarding future revenue streams from cadisegliatin if it reaches commercialization.

AI Generated Analysis | Feedback

Share Issuance

    In September 2025, vTv Therapeutics completed an $80 million private placement with new and existing healthcare investors, including the T1D Fund, with proceeds intended to fund the CATT1 Phase 3 trial and program development.
    In August 2025, the company agreed to issue and sell 5,243,732 Units in a private placement, comprising 682,018 shares of Class A common stock at $15.265 per share, along with pre-funded warrants.
    On November 20, 2023, vTv Therapeutics effected a 1-for-40 reverse stock split.

Inbound Investments

    In September 2025, vTv Therapeutics secured an $80 million private placement from new and existing healthcare institutional investors and the T1D Fund, which is expected to fund the CATT1 Phase 3 trial.
    On June 1, 2022, G42 Investments AI Holding RSC Ltd made a $25 million investment in vTv Therapeutics, acquiring 10,386,274 shares of Class A Common Stock, with the funding designated for a substantial portion of Phase 3 clinical trials for TTP399 (cadisegliatin) in the U.S.

Outbound Investments

    vTv Therapeutics's most recent "exit" was from an Early Stage VC deal with Anteris Bio on December 11, 2020, which is indicative of an investment made by vTv Therapeutics.

Capital Expenditures

    The company's Research & Development (R&D) expenses increased to $7.0 million in Q3 2025 from $3.2 million in Q3 2024, reflecting higher spending on cadisegliatin and other projects.
    General & Administrative (G&A) expenses also saw an increase to $3.7 million in Q3 2025 from $3.3 million in Q3 2024, primarily due to increases in payroll and legal expenses.
    As of March 31, 2025, the company indicated that debt financing might limit its ability to make capital expenditures.

Better Bets than vTv Therapeutics (VTVT)

	VTVT	Better Performance than VTVT
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	-98.3%	ABBV (7.4%), AMGN (10.6%), GILD (2.8%), VRTX (10.3%), REGN (2.9%)
Rev Chg 3Y Avg	3604.3%	VRDN (7748.5%), CRMD (5669.1%), KROS (15245.3%), ACIU (1365670.2%)
Op Mgn LTM	-150717.6%	ABBV (24.1%), AMGN (24.1%), GILD (38.3%), VRTX (-0.8%), REGN (26.7%)
CFO/Rev LTM	-129558.8%	ABBV (35.0%), AMGN (36.5%), GILD (33.2%), VRTX (31.7%), REGN (35.6%)
FCF/Rev LTM	-129558.8%	ABBV (33.0%), AMGN (32.1%), GILD (31.5%), VRTX (28.5%), REGN (27.2%)
Total Yield	-9.6%	ABBV (3.4%), AMGN (6.7%), GILD (7.8%), VRTX (3.3%), REGN (6.8%)

	VTVT	Better Performance than VTVT
Metric	Value	Sector (Health Care)
Rev Chg LTM	-98.3%	LLY (36.8%), JNJ (5.1%), ABBV (7.4%), UNH (10.5%), MRK (1.7%)
Rev Chg 3Y Avg	3604.3%	VRDN (7748.5%), CRMD (5669.1%), KROS (15245.3%), ACIU (1365670.2%), BIAF (10647.3%)
Op Mgn LTM	-150717.6%	LLY (43.0%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%), MRK (34.9%)
CFO/Rev LTM	-129558.8%	LLY (20.5%), JNJ (26.3%), ABBV (35.0%), UNH (4.8%), MRK (26.6%)
FCF/Rev LTM	-129558.8%	LLY (-0.1%), JNJ (20.3%), ABBV (33.0%), UNH (4.0%), MRK (20.3%)
Total Yield	-9.6%	LLY (2.0%), JNJ (7.9%), ABBV (3.4%), UNH (8.7%), MRK (11.7%)

	VTVT	Better Performance than VTVT
Metric	Value	All Other Sectors
Rev Chg LTM	-98.3%	NVDA (71.6%), AAPL (6.0%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%)
Rev Chg 3Y Avg	3604.3%	UEC (10082.6%), DBRG (13055.0%), VYX (9716.9%), PFLT (12481.5%), URG (21494.7%)
Op Mgn LTM	-150717.6%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM	-129558.8%	NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM	-129558.8%	NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-9.6%	NVDA (1.9%), AAPL (2.8%), MSFT (3.4%), GOOGL (4.0%), AMZN (2.8%)

		Best Bets In Health Care Sector
	VTVT	RPRX	HALO	DOCS	CPRX	BMY	MEDP	PBH	MRK	NBIX	ISRG
What You Pay
P/E	-10.4	22.1	13.8	36.8	13.1	15.7	38.3	14.6	12.2	33.6	71.3
P/EBIT	-8.3	10.7	10.7	37.7	11.0	9.5	32.7	9.0	10.0	24.7	69.6
What You Get
Rev Chg Q	�	7.9%	22.1%	23.2%	15.3%	2.8%	23.7%	-3.4%	3.7%	27.8%	22.9%
Rev Chg LTM	-98.3%	3.7%	31.2%	20.2%	25.6%	1.3%	13.9%	-0.0%	1.7%	19.6%	22.2%
Rev Chg 3Y Avg	3,604.3%	1.5%	29.0%	17.4%	46.5%	1.0%	19.9%	0.1%	2.9%	24.6%	16.3%
FCF/Rev 3Y Avg	-144,061.5%	115.2%	45.0%	42.7%	34.2%	29.0%	25.3%	21.7%	22.0%	21.1%	16.5%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Would You Still Hold vTv Therapeutics Stock If It Fell 30%?	Return

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to VTVT. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-11.9%	-11.9%	-11.9%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.3%	-0.3%	-5.8%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-31.5%	-31.5%	-31.5%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-1.6%	-1.6%	-1.9%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	15.6%	15.6%	-7.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-11.9%	-11.9%	-11.9%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.3%	-0.3%	-5.8%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-31.5%	-31.5%	-31.5%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-1.6%	-1.6%	-1.9%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	15.6%	15.6%	-7.0%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
CDTX	Cidara Therapeutics	3.4	105.4%	709.9%
PGEN	Precigen	1.4	25.6%	333.0%
SRRK	Scholar Rock	4.2	24.4%	-13.4%
AVDL	Avadel Pharmaceuticals	2.3	22.5%	124.2%
SEPN	Septerna	1.0	20.9%	1.6%
CSIQ	Canadian Solar	2.3	17.3%	202.0%
DNTH	Dianthus Therapeutics	1.5	15.1%	87.4%
ANGX	Angel Studios	1.0	13.9%
EWTX	Edgewise Therapeutics	2.4	11.4%	-14.8%
FLNC	Fluence Energy	2.3	10.2%	12.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
AVXL	Anavex Life Sciences	0.3	-35.9%	-66.1%
SOC	Sable Offshore	0.4	-28.9%	-81.7%
STUB	Stubhub	4.9	-21.0%
DEFT	DeFi Technologies	0.4	-15.2%
NGNE	Neurogene	0.5	-14.0%	-0.4%
ECX	ECARX	0.7	-10.9%	0.9%
MNPR	Monopar Therapeutics	0.5	-10.4%	254.5%
TWST	Twist Bioscience	1.6	-10.1%	-42.2%
PLUG	Plug Power	2.5	-9.8%	5.4%
RSKD	Riskified	0.7	-9.8%	-4.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
LXP	LXP Industrial Trust	13.4	378.3%	18.7%
COGT	Cogent Biosciences	3.8	126.3%	330.0%
CDTX	Cidara Therapeutics	3.4	108.6%	709.9%
MH	McGraw Hill	3.0	38.7%
EWTX	Edgewise Therapeutics	2.4	32.6%	-14.8%
SRRK	Scholar Rock	4.2	29.2%	-13.4%
KALV	KalVista Pharmaceuticals	0.7	26.3%	60.8%
AVDL	Avadel Pharmaceuticals	2.3	26.1%	124.2%
REAL	RealReal	1.6	26.0%	26.7%
SEPN	Septerna	1.0	25.7%	1.6%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
BTDR	Bitdeer Technologies	2.0	-52.2%	-51.5%
AVXL	Anavex Life Sciences	0.3	-50.0%	-66.1%
CTEV	Claritev	0.7	-37.5%
ARDT	Ardent Health	1.3	-37.4%	-47.2%
WYFI	Whitefiber	0.7	-37.4%
PSFE	Paysafe	0.4	-31.4%	-59.2%
CIFR	Cipher Mining	5.4	-30.6%	209.5%
NKLR	Terra Innovatum Global	0.3	-29.9%
CLSK	Cleanspark	3.1	-29.6%	19.0%
HIVE	HIVE Digital Technologies	0.6	-29.6%	16.1%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TERN	Terns Pharmaceuticals	2.1	162.0%	307.2%
VTYX	Ventyx Biosciences	0.7	131.2%	322.4%
INBX	Inhibrx Biosciences	1.2	116.2%	413.8%
CSIQ	Canadian Solar	2.3	114.7%	202.0%
CDTX	Cidara Therapeutics	3.4	113.4%	709.9%
COGT	Cogent Biosciences	3.8	105.0%	330.0%
PUMP	ProPetro	1.0	93.8%	6.3%
REPL	Replimune	0.8	92.5%	-25.8%
MBX	MBX Biosciences	0.8	80.0%	34.5%
CELC	Celcuity	4.0	76.4%	608.0%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SOC	Sable Offshore	0.4	-68.1%	-81.7%
NTLA	Intellia Therapeutics	0.9	-65.1%	-25.4%
NKLR	Terra Innovatum Global	0.3	-64.0%
ASPN	Aspen Aerogels	0.3	-62.9%	-74.1%
CCOI	Cogent Communications	0.8	-60.9%	-75.7%
AVXL	Anavex Life Sciences	0.3	-59.5%	-66.1%
BTDR	Bitdeer Technologies	2.0	-59.4%	-51.5%
METC	Ramaco Resources	1.2	-56.4%	113.5%
LRN	Stride	2.8	-54.4%	-38.3%
FMC	FMC	1.7	-53.6%	-70.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
CDTX	Cidara Therapeutics	3.4	105.4%	709.9%
PGEN	Precigen	1.4	25.6%	333.0%
SRRK	Scholar Rock	4.2	24.4%	-13.4%
AVDL	Avadel Pharmaceuticals	2.3	22.5%	124.2%
SEPN	Septerna	1.0	20.9%	1.6%
CSIQ	Canadian Solar	2.3	17.3%	202.0%
DNTH	Dianthus Therapeutics	1.5	15.1%	87.4%
ANGX	Angel Studios	1.0	13.9%
EWTX	Edgewise Therapeutics	2.4	11.4%	-14.8%
FLNC	Fluence Energy	2.3	10.2%	12.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
AVXL	Anavex Life Sciences	0.3	-35.9%	-66.1%
SOC	Sable Offshore	0.4	-28.9%	-81.7%
STUB	Stubhub	4.9	-21.0%
DEFT	DeFi Technologies	0.4	-15.2%
NGNE	Neurogene	0.5	-14.0%	-0.4%
ECX	ECARX	0.7	-10.9%	0.9%
MNPR	Monopar Therapeutics	0.5	-10.4%	254.5%
TWST	Twist Bioscience	1.6	-10.1%	-42.2%
PLUG	Plug Power	2.5	-9.8%	5.4%
RSKD	Riskified	0.7	-9.8%	-4.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
LXP	LXP Industrial Trust	13.4	378.3%	18.7%
COGT	Cogent Biosciences	3.8	126.3%	330.0%
CDTX	Cidara Therapeutics	3.4	108.6%	709.9%
MH	McGraw Hill	3.0	38.7%
EWTX	Edgewise Therapeutics	2.4	32.6%	-14.8%
SRRK	Scholar Rock	4.2	29.2%	-13.4%
KALV	KalVista Pharmaceuticals	0.7	26.3%	60.8%
AVDL	Avadel Pharmaceuticals	2.3	26.1%	124.2%
REAL	RealReal	1.6	26.0%	26.7%
SEPN	Septerna	1.0	25.7%	1.6%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
BTDR	Bitdeer Technologies	2.0	-52.2%	-51.5%
AVXL	Anavex Life Sciences	0.3	-50.0%	-66.1%
CTEV	Claritev	0.7	-37.5%
ARDT	Ardent Health	1.3	-37.4%	-47.2%
WYFI	Whitefiber	0.7	-37.4%
PSFE	Paysafe	0.4	-31.4%	-59.2%
CIFR	Cipher Mining	5.4	-30.6%	209.5%
NKLR	Terra Innovatum Global	0.3	-29.9%
CLSK	Cleanspark	3.1	-29.6%	19.0%
HIVE	HIVE Digital Technologies	0.6	-29.6%	16.1%

Peer Comparisons for vTv Therapeutics

Financials

	VTVT	VRTX	APM	BBOT	GDTC	HIND	Median
Name	vTv Ther.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Price	30.80	437.15	1.38	13.12	1.96	4.87	8.99
Mkt Cap	0.2	111.7	-	-	-	-	56.0
Rev LTM	0	11,723	-	0	-	-	0
Op Inc LTM	-26	-92	-	-93	-	-	-92
FCF LTM	-22	3,337	-	-60	-	-	-22
FCF 3Y Avg	-24	2,064	-	-	-	-	1,020
CFO LTM	-22	3,718	-	-60	-	-	-22
CFO 3Y Avg	-24	2,419	-	-	-	-	1,198

Growth & Margins

	VTVT	VRTX	APM	BBOT	GDTC	HIND	Median
Name	vTv Ther.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Rev Chg LTM	-98.3%	10.3%	-	-	-	-	-44.0%
Rev Chg 3Y Avg	3,604.3%	10.5%	-	-	-	-	1,807.4%
Rev Chg Q	-	11.0%	-	-	-	-	11.0%
QoQ Delta Rev Chg LTM	0.0%	2.7%	-	-	-	-	1.3%
Op Mgn LTM	-150,717.6%	-0.8%	-	-	-	-	-75,359.2%
Op Mgn 3Y Avg	-152,701.1%	26.2%	-	-	-	-	-76,337.5%
QoQ Delta Op Mgn LTM	-3,329.4%	1.0%	-	-	-	-	-1,664.2%
CFO/Rev LTM	-129,558.8%	31.7%	-	-	-	-	-64,763.6%
CFO/Rev 3Y Avg	-144,061.5%	23.1%	-	-	-	-	-72,019.2%
FCF/Rev LTM	-129,558.8%	28.5%	-	-	-	-	-64,765.2%
FCF/Rev 3Y Avg	-144,061.5%	19.8%	-	-	-	-	-72,020.9%

Valuation

	VTVT	VRTX	APM	BBOT	GDTC	HIND	Median
Name	vTv Ther.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Cap	0.2	111.7	-	-	-	-	56.0
P/S	11,934.2	9.5	-	-	-	-	5,971.9
P/EBIT	-8.3	25.0	-	-	-	-	8.4
P/E	-10.4	30.4	-	-	-	-	10.0
P/CFO	-9.2	30.1	-	-	-	-	10.4
Total Yield	-9.6%	3.3%	-	-	-	-	-3.2%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-28.5%	2.3%	-	-	-	-	-13.1%
D/E	0.0	0.0	-	-	-	-	0.0
Net D/E	-0.1	-0.0	-	-	-	-	-0.1

Returns

	VTVT	VRTX	APM	BBOT	GDTC	HIND	Median
Name	vTv Ther.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
1M Rtn	37.4%	7.2%	-12.1%	9.8%	-12.9%	-8.6%	-0.7%
3M Rtn	99.5%	11.3%	-0.7%	23.2%	8.9%	-65.2%	10.1%
6M Rtn	46.5%	-0.3%	44.9%	-	-12.3%	-	22.3%
12M Rtn	96.9%	-9.7%	25.5%	-	-7.5%	-	9.0%
3Y Rtn	-12.5%	43.2%	-79.4%	-	-	-	-12.5%
1M Excs Rtn	46.6%	5.4%	-10.8%	13.5%	-14.5%	-5.3%	0.0%
3M Excs Rtn	94.0%	7.7%	-2.9%	4.2%	5.7%	-48.6%	4.9%
6M Excs Rtn	33.4%	-13.4%	31.9%	-	-25.3%	-	9.3%
12M Excs Rtn	108.9%	-23.3%	2.5%	-	-26.1%	-	-10.4%
3Y Excs Rtn	-96.0%	-38.3%	-158.2%	-	-	-	-96.0%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/12/2025	3/20/2025	3/13/2024	3/6/2023	3/29/2022	2/24/2021	2/21/2020
Key Financials
Total Revenue	0	1	0	2	4	6	3
EBITDA	-24	-23	-26	-25	-18	-12	-20
Operating Income	-26	-24	-26	-23	-22	-12	-21
Net Income	-20	-18	-20	-19	-13	-8	-13
EPS	-3.12	-3.20	-9.71	-9.98	-8.29	-7.20	-23.60
Growth Rates
Total Revenue Growth	-98.3%	∞%	-100.0%	-49.6%	-37.6%	132.1%	-77.8%
EBITDA Growth	4.7%	12.9%	-4.4%	-41.4%	-45.8%	39.8%	0.8%
Operating Income Growth	-12.1%	5.2%	-13.1%	-4.1%	-82.8%	43.3%	-5.4%
Net Income Growth	3.1%	8.8%	-5.7%	-47.6%	-52.8%	34.8%	-64.9%
Margins
EBITDA Margin	-143794.1%	-2214.0%	-	-1227.3%	-437.3%	-187.3%	-722.6%
Operating Income Margin	-150717.6%	-2377.6%	-	-1116.9%	-540.9%	-184.8%	-755.9%
Net Income Margin	-115029.4%	-1815.3%	-	-949.7%	-324.3%	-132.5%	-471.9%
Cash & Debt
Total Cash	26	37	9	12	13	6	2
Total Debt	0	0	1	1	1	1	7
Net Debt / (Cash)	-26	-37	-9	-11	-12	-5	5
Cash Flows
Net Cash from Operations	-22	-25	-19	-16	-19	-18	-23
Free Cash from Operations	-22	-25	-19	-16	-19	-18	-23
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/12/2025	5/15/2025	3/20/2025	11/12/2024	8/8/2024	5/9/2024	3/13/2024	11/9/2023	8/11/2023	5/11/2023	3/6/2023	11/10/2022
Key Financials Quarterly
Total Revenue	0	0	0	0	0	1	0	0	0	0	0	0
Ebitda	-8	-6	-4	-6	-7	-6	-4	-9	-7	-7	-6	-5
Operating Income	-8	-7	-5	-7	-7	-6	-5	-5	-8	-7	-6	-6
Net Income	-6	-5	-4	-5	-5	-5	-3	-7	-6	-4	-5	-4
EPS	-0.92	-0.77	-0.55	-0.88	-0.81	-1.17	-1.67	-3.19	-2.69	-2.16	-2.40	-2.00
Key Financials TTM
Total Revenue TTM	0	0	1	1	1	1	0	0	0	0	2	2
Ebitda TTM	-24	-24	-23	-23	-26	-26	-28	-29	-26	-23	-25	-28
Operating Income TTM	-26	-25	-24	-24	-23	-24	-26	-27	-27	-23	-23	-27
Net Income TTM	-20	-19	-18	-18	-20	-21	-20	-22	-19	-17	-19	-21
Growth Rates Quarterly
Total Revenue Growth	-	-100.0%	-	-	-	-	-100.0%	-	-100.0%	-100.0%	0.0%	-100.0%
EBITDA Growth	-8.2%	-15.9%	-0.1%	31.7%	0.8%	24.3%	27.2%	-56.6%	-76.6%	19.5%	35.9%	-306.6%
Operating Income Growth	-7.9%	-15.6%	-3.9%	-21.2%	10.6%	24.2%	25.8%	5.6%	-98.7%	-14.6%	42.9%	-254.9%
Net Income Growth	-16.7%	-4.7%	-4.5%	28.1%	7.8%	-8.1%	26.7%	-56.2%	-78.3%	35.8%	32.7%	-292.0%
Margins Quarterly
EBITDA Margin	-	-	-25970.6%	-	-	-560.5%	-	-	-	-	-67344.4%	-
Operating Income Margin	-	-	-28776.5%	-	-	-562.7%	-	-	-	-	-70477.8%	-
Net Income Margin	-	-	-21376.5%	-	-	-486.5%	-	-	-	-	-52722.2%	-
Cash & Debt
Total Cash	26	31	37	42	46	52	9	8	13	19	12	15
Total Debt	0	0	0	0	0	0	1	1	0	0	1	1
Net Debt / (Cash)	-26	-31	-37	-41	-45	-52	-9	-7	-12	-18	-11	-14
Cash Flows Quarterly
FCF from Operations	-5	-6	-5	-6	-7	-7	-3	-5	-6	-5	-7	-9
Cash Flows TTM
FCF from Operations TTM	-22	-24	-25	-23	-22	-21	-19	-23	-27	-20	-16	-16
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-10.7%	-9.2%	-7.1%	-9.6%	-10.9%	-8.8%	-7.6%	-8.6%	-13.2%	-12.5%	-10.4%	-9.6%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-8.9%	-8.9%	-8.8%	-8.9%	-8.7%	-9.3%	-10.3%	-10.9%	-11.3%	-9.9%	-9.3%	-11.6%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	0	2	4	6	3
Total	0	2	4	6	3

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	11
Total	11

Price Behavior

Price Behavior

Market Price	$30.80
Market Cap ($ Bil)	0.2
First Trading Date	07/30/2015
Distance from 52W High	-1.5%
	50 Days	200 Days
DMA Price	$22.31	$18.48
DMA Trend	up	up
Distance from DMA	38.0%	66.6%
	3M	1YR
Volatility	56.8%	91.4%
Downside Capture	-156.47	74.34
Upside Capture	267.74	133.63
Correlation (SPY)	14.1%	25.5%

VTVT Betas & Captures as of 10/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.12	0.56	0.45	0.43	1.14	0.88
Up Beta	1.18	0.08	-0.56	-0.17	1.50	0.98
Down Beta	2.51	1.85	1.89	2.13	0.77	1.49
Up Capture	-37%	126%	110%	15%	119%	14%
Bmk +ve Days	14	27	37	74	145	425
Stock +ve Days	12	26	33	55	108	340
Down Capture	67%	-153%	-124%	10%	89%	90%
Bmk -ve Days	9	17	28	53	106	327
Stock -ve Days	10	17	26	60	129	383

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of VTVT With Other Asset Classes (Last 1Y)
	VTVT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	138.2%	3.0%	13.3%	55.3%	3.7%	-3.3%	12.2%
Annualized Volatility	91.5%	17.2%	19.5%	19.7%	16.0%	17.8%	35.4%
Sharpe Ratio	1.37	0.01	0.51	2.12	0.04	-0.34	0.32
Correlation With Other Assets		19.7%	25.3%	4.8%	16.2%	23.6%	12.0%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of VTVT With Other Asset Classes (Last 5Y)
	VTVT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-14.3%	8.3%	15.5%	15.5%	13.1%	6.1%	45.1%
Annualized Volatility	99.2%	14.4%	17.1%	15.7%	18.9%	19.1%	49.1%
Sharpe Ratio	0.25	0.40	0.74	0.79	0.57	0.24	0.72
Correlation With Other Assets		9.6%	14.7%	3.1%	4.1%	11.6%	13.7%

Based On 10-Year Data

		Comparison of VTVT With Other Asset Classes (Last 10Y)
	VTVT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-19.9%	9.6%	14.2%	13.7%	5.3%	5.4%	74.8%
Annualized Volatility	118.8%	16.7%	18.1%	14.8%	17.7%	20.9%	56.0%
Sharpe Ratio	0.30	0.47	0.68	0.76	0.23	0.23	0.94
Correlation With Other Assets		9.6%	11.5%	3.5%	4.4%	9.3%	7.9%

Short Interest

Short Interest: As Of Date	10312025
Short Interest: Shares Quantity	19,468
Short Interest: % Change Since 10152025	-14.6%
Average Daily Volume	3,195
Days-to-Cover Short Interest	6.09
Basic Shares Quantity	6,587,070
Short % of Basic Shares	0.3%

Returns Analyses

	Title
0	Would You Still Hold vTv Therapeutics Stock If It Fell 30%?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/6/2025	2.2%
8/12/2025	-3.2%	7.1%	38.4%
3/20/2025	-5.5%	-2.6%	11.7%
11/12/2024	7.1%	18.1%	12.9%
8/8/2024	-1.8%	0.0%	12.3%
5/9/2024	-3.1%	3.9%	-32.6%
2/28/2024	95.9%	61.6%	180.0%
8/11/2023	2.6%	-6.9%	-32.7%
...
SUMMARY STATS
# Positive	9	10	9
# Negative	11	10	11
Median Positive	2.6%	3.6%	12.9%
Median Negative	-3.1%	-5.4%	-16.8%
Max Positive	95.9%	61.6%	180.0%
Max Negative	-11.7%	-16.9%	-48.7%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8122025	10-Q 6/30/2025
3312025	5152025	10-Q 3/31/2025
12312024	3202025	10-K 12/31/2024
9302024	11122024	10-Q 9/30/2024
6302024	8082024	10-Q 6/30/2024
3312024	5092024	10-Q 3/31/2024
12312023	3132024	10-K 12/31/2023
9302023	11092023	10-Q 9/30/2023
6302023	8112023	10-Q 6/30/2023
3312023	5112023	10-Q 3/31/2023
12312022	3062023	10-K 12/31/2022
9302022	11102022	10-Q 9/30/2022
6302022	8152022	10-Q 6/30/2022
3312022	5122022	10-Q 3/31/2022
12312021	3292022	10-K 12/31/2021
9302021	11092021	10-Q 9/30/2021

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

vTv Therapeutics (VTVT)

Market Price (11/15/2025): $30.39 | Market Cap: $200.2 MilSector: Health Care | Industry: Biotechnology

vTv Therapeutics (VTVT)

Market Price (11/15/2025): $30.39Market Cap: $200.2 MilSector: Health CareIndustry: Biotechnology

Market Valuation & Key Metrics

VTVT Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About vTv Therapeutics (VTVT)

Cadisegliatin (TTP399) for Type 1 Diabetes

HPP737 for Psoriasis

Interactive Breakdown

Better Bets than vTv Therapeutics (VTVT)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for vTv Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (11/15/2025): $30.39 | Market Cap: $200.2 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (11/15/2025): $30.39
Market Cap: $200.2 Mil
Sector: Health Care
Industry: Biotechnology